Precision Drilling
PDS
Lantheus
LNTH
eBay
EBAY
4
DexCom
DXCM
5
Collegium Pharmaceutical
COLL
US Stock MarketDetailed Quotes
KAPA Kairos Pharma
- 0.936
- +0.015+1.61%
Close Mar 31 16:00 ET
12.83MMarket Cap-4.46P/E (TTM)
1.001High0.900Low46.18KVolume0.970Open0.921Pre Close43.52KTurnover2.98%Turnover RatioLossP/E (Static)13.70MShares4.00052wk High3.85P/B1.45MFloat Cap0.85152wk Low--Dividend TTM1.55MShs Float4.000Historical High--Div YieldTTM10.98%Amplitude0.851Historical Low0.942Avg Price1Lot Size
About Kairos Pharma Company
Kairos Pharma Ltd. is a clinical-stage biopharmaceutical company, which engages in the development of novel and transformative drug therapies to treat cancer. It focuses on the research and development of immunotherapies for oncology. The company was founded by John S. Yu on June 17, 2013 and is headquartered in Los Angeles, CA.
Company Profile
SymbolKAPA
Company NameKairos Pharma
Listing DateSep 16, 2024
Founded2013
CEODr. John S. Yu,M.D.
MarketAMEX
Employees3
Fiscal Year Ends12-31
Address2355 Westwood Boulevard,Suite 139
CityLos Angeles
ProvinceCalifornia
CountryUnited States of America
Zip Code90064
Phone1-310-948-2356
Websitehttp://kairospharma.com
Company Executives
- Name
- Position
- Salary
- Dr. John S. Yu,M.D.
- Chairman of the Board and Chief Executive Officer
- --
- Neil Bhowmick
- Chief Scientific Officer
- --
- Doug Samuelson
- Chief Financial Officer
- --
- Ramachandran Murali, PhD
- Vice President of Research and Development
- --
- Dr. Rahul Singhvi, Sc.D.
- Director
- --
- Hyun W. Bae, M.D.
- Independent Director
- --
- Dr. Hansoo Michael Keyoung, M.D.,PhD
- Independent Director
- --
Market Insights
Discussing
Trump 2.0 Era: How will global markets evolve?
🎙️Discussion: 1. How will tariff policies affect the movement of key assets such as U.S. stocks, gold, and Bitcoin? 2. Given this context,
Moo Live
Jan 23 16:54
MicroStrategy Q4 2024 earnings conference call